Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy.
Heparin is the drug of choice for the treatment or the prevention of thromboembolic disease during pregnancy. However, treatment options are limited when heparin cannot be used because of hypersensitivity skin reactions. Despite the recent availability of new anticoagulant agents, data relating to their use during pregnancy are lacking. This report describes the successful management with fondaparinux, during 150 days, of a pregnant patient with protein S deficiency and prior deep vein thrombosis (DVT) who developed heparin and danaparoid hypersensitivity.
Mazzolai
Lucia
L
Service of Vascular Medicine, University Hospital of Lausanne (CHUV), Av Pierre Decker 5, 1011 Lausanne, Switerland. lucia.mazzolai@chuv.ch
Hohlfeld
Patrick
P
Spertini
Francois
F
Hayoz
Daniel
D
Schapira
Marc
M
Duchosal
Michel A
MA
D000328:Adult; D005260:Female; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy*; D018455:Protein S Deficiency / Q000188:drug therapy / Q000235:genetics; D013923:Thromboembolism / Q000235:genetics
D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux